Author

Mathurin Fumery

COLONIC CROHN’S DISEASE IS ASSOCIATED WITH A PEJORATIVE DISEASE COURSE OF PEDIATRIC-ONSET CROHN'S DISEASE: A TWO DECADES POPULATION-BASED STUDY
COLONIC CROHN’S DISEASE IS ASSOCIATED WITH A PEJORATIVE DISEASE COURSE OF PEDIATRIC-ONSET CROHN'S DISEASE: A TWO DECADES POPULATION-BASED STUDY

Mathurin Fumery  et al.

EFFECTIVENESS AND SAFETY OF RISANKIZUMAB INDUCTION THERAPY IN PATIENTS WITH CROHN’S DISEASE: A GETAID COHORT STUDY
EFFECTIVENESS AND SAFETY OF RISANKIZUMAB INDUCTION THERAPY IN PATIENTS WITH CROHN’S DISEASE: A GETAID COHORT STUDY

Mathurin Fumery  et al.

COMPARISON OF THE RISK OF CROHN'S DISEASE POSTOPERATIVE RECURRENCE BETWEEN MODIFIED RUTGEERTS SCORE I2A AND I2B CATEGORIES: AN INDIVIDUAL PATIENT DATA META-ANALYSIS
COMPARISON OF THE RISK OF CROHN'S DISEASE POSTOPERATIVE RECURRENCE BETWEEN MODIFIED RUTGEERTS SCORE I2A AND I2B CATEGORIES: AN INDIVIDUAL PATIENT DATA META-ANALYSIS

REAL-WORLD COMPARISON OF EFFECTIVENESS BETWEEN USTEKINUMAB AND VEDOLIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS EXPOSED TO AT LEAST ONE ANTI-TNF AGENT
REAL-WORLD COMPARISON OF EFFECTIVENESS BETWEEN USTEKINUMAB AND VEDOLIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS EXPOSED TO AT LEAST ONE ANTI-TNF AGENT

Mathurin Fumery  et al.

THE BURDEN OF BOWEL URGENCY IN ULCERATIVE COLITIS: A FRENCH MULTICENTRIC REAL-LIFE STUDY (THEFAR)
THE BURDEN OF BOWEL URGENCY IN ULCERATIVE COLITIS: A FRENCH MULTICENTRIC REAL-LIFE STUDY (THEFAR)

Mathurin Fumery  et al.

IMPACT OF BIOLOGICS ON THE RISK OF EARLY POSTOPERATIVE COMPLICATIONS IN CROHN'S DISEASE: A FRENCH NATIONWIDE STUDY
IMPACT OF BIOLOGICS ON THE RISK OF EARLY POSTOPERATIVE COMPLICATIONS IN CROHN'S DISEASE: A FRENCH NATIONWIDE STUDY

Mathurin Fumery  et al.

EFFECTIVENESS AND SAFETY OF RISANKIZUMAB INDUCTION THERAPY IN PATIENTS WITH CROHN’S DISEASE: A GETAID COHORT STUDY
EFFECTIVENESS AND SAFETY OF RISANKIZUMAB INDUCTION THERAPY IN PATIENTS WITH CROHN’S DISEASE: A GETAID COHORT STUDY

PERFUSE: A FRENCH NON-INTERVENTIONAL COHORT STUDY OF ADALIMUMAB-NAÏVE AND TRANSITIONED PATIENTS RECEIVING ADALIMUMAB BIOSIMILAR SB5; BASELINE RESULTS
PERFUSE: A FRENCH NON-INTERVENTIONAL COHORT STUDY OF ADALIMUMAB-NAÏVE AND TRANSITIONED PATIENTS RECEIVING ADALIMUMAB BIOSIMILAR SB5; BASELINE RESULTS

Mathurin Fumery  et al.

IGA VASCULITIS ASSOCIATED WITH INFLAMMATORY BOWEL DISEASES: A MULTICENTER STUDY OF THE GETAID AND GFEV
IGA VASCULITIS ASSOCIATED WITH INFLAMMATORY BOWEL DISEASES: A MULTICENTER STUDY OF THE GETAID AND GFEV

Mathurin Fumery  et al.

WHICH SECOND-LINE BIOLOGIC AFTER ANTI-TNF FAILURE DURING CROHN'S DISEASE: USTEKINUMAB OR VEDOLIZUMAB, A MULTICENTRE RETROSPECTIVE STUDY
WHICH SECOND-LINE BIOLOGIC AFTER ANTI-TNF FAILURE DURING CROHN'S DISEASE: USTEKINUMAB OR VEDOLIZUMAB, A MULTICENTRE RETROSPECTIVE STUDY

Mathurin Fumery  et al.

REAL-WORLD MULTICENTER COMPARISON OF SHORT AND LONG-TERM EFFECTIVENESS AND SAFETY BETWEEN TOFACITINIB AND VEDOLIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS AFTER FAILURE TO AT LEAST ONE ANTI-TNF AGENT
REAL-WORLD MULTICENTER COMPARISON OF SHORT AND LONG-TERM EFFECTIVENESS AND SAFETY BETWEEN TOFACITINIB AND VEDOLIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS AFTER FAILURE TO AT LEAST ONE ANTI-TNF AGENT

Mathurin Fumery  et al.

USTEKINUMAB IS MORE EFFECTIVE THAN AZATHIOPRINE TO PREVENT ENDOSCOPIC POSTOPERATIVE RECURRENCE IN CROHN´S DISEASE
USTEKINUMAB IS MORE EFFECTIVE THAN AZATHIOPRINE TO PREVENT ENDOSCOPIC POSTOPERATIVE RECURRENCE IN CROHN´S DISEASE

Mathurin Fumery  et al.

ULTRASOUND IS EFFECTIVE TO IDENTIFY MUCOSAL HEALING IN CROHN'S DISEASE PATIENTS : RESULTS OF A CROSS-SECTIONAL STUDY
ULTRASOUND IS EFFECTIVE TO IDENTIFY MUCOSAL HEALING IN CROHN'S DISEASE PATIENTS : RESULTS OF A CROSS-SECTIONAL STUDY

Mathurin Fumery  et al.

NO BENEFIT OF CONCOMITANT IMMUNOMODULATOR THERAPY ON EFFICACY OF NON - ANTI-TNF BIOLOGICS IN INFLAMMATORY BOWEL DISEASES: A META-ANALYSIS
NO BENEFIT OF CONCOMITANT IMMUNOMODULATOR THERAPY ON EFFICACY OF NON - ANTI-TNF BIOLOGICS IN INFLAMMATORY BOWEL DISEASES: A META-ANALYSIS

Mathurin Fumery  et al.

LONG-TERM EFFECTIVENESS AND ACCEPTABILITY OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES: THE REMSWITCH-LT STUDY
LONG-TERM EFFECTIVENESS AND ACCEPTABILITY OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES: THE REMSWITCH-LT STUDY

Mathurin Fumery  et al.

COMPLETE ENDOSCOPIC HEALING IS ASSOCIATED WITH LOWER DISABILITY THAN PARTIAL MUCOSAL HEALING IN CROHN’S DISEASE: A PROSPECTIVE MULTICENTRIC STUDY
COMPLETE ENDOSCOPIC HEALING IS ASSOCIATED WITH LOWER DISABILITY THAN PARTIAL MUCOSAL HEALING IN CROHN’S DISEASE: A PROSPECTIVE MULTICENTRIC STUDY

Mathurin Fumery  et al.

INCREASED INCIDENCE OF CANCER AND MORTALITY IN A PEDIATRIC-ONSET IBD POPULATION-BASED COHORT OF 1344 PATIENTS DIAGNOSED BETWEEN 1988 AND 2011: THE INSPIRED STUDY
INCREASED INCIDENCE OF CANCER AND MORTALITY IN A PEDIATRIC-ONSET IBD POPULATION-BASED COHORT OF 1344 PATIENTS DIAGNOSED BETWEEN 1988 AND 2011: THE INSPIRED STUDY

Mathurin Fumery  et al.

CHANGING THE COURSE OF CROHN’S DISEASE WITH AN EARLY USE OF ADALIMUMAB: THE CURE STUDY FROM THE GETAID
CHANGING THE COURSE OF CROHN’S DISEASE WITH AN EARLY USE OF ADALIMUMAB: THE CURE STUDY FROM THE GETAID

Mathurin Fumery  et al.

NEW THERAPEUTIC STRATEGIES HAVE CHANGED THE NATURAL HISTORY OF PAEDIATRIC INFLAMMATORY BOWEL DISEASES: RESULTS FROM A POPULATION-BASED COHORT OVER A 24-YEAR PERIOD (1988-2011)
NEW THERAPEUTIC STRATEGIES HAVE CHANGED THE NATURAL HISTORY OF PAEDIATRIC INFLAMMATORY BOWEL DISEASES: RESULTS FROM A POPULATION-BASED COHORT OVER A 24-YEAR PERIOD (1988-2011)

Mathurin Fumery  et al.

REAL-WORLD COMPARISON OF EFFECTIVENESS BETWEEN TOFACITINIB AND USTEKINUMAB IN PATIENTS WITH ULCERATIVE COLITIS EXPOSED TO AT LEAST ONE ANTI-TNF AGENT: LONG-TERM RESULTS FROM THE TORUS STUDY
REAL-WORLD COMPARISON OF EFFECTIVENESS BETWEEN TOFACITINIB AND USTEKINUMAB IN PATIENTS WITH ULCERATIVE COLITIS EXPOSED TO AT LEAST ONE ANTI-TNF AGENT: LONG-TERM RESULTS FROM THE TORUS STUDY

Mathurin Fumery  et al.

Item 1 - 20 / 29
1
2